DelveInsight's "ROZLYTREK Market Size, Forecast, and Market Insight Report" highlights the details around ROZLYTREK, an ...
It also targets ROS1 and ALK, with IC50 values ranging from 0.1 to 2 nM, while showing weaker inhibition of JAK2 and TNK2 (IC50 > 5 nM). The primary active metabolite, M5, exhibits similar ...
It also targets ROS1 and ALK, with IC50 values ranging from 0.1 to 2 nM, while showing weaker inhibition of JAK2 and TNK2 (IC50 > 5 nM). The primary active metabolite, M5, exhibits similar ...
As biomarker testing and the demand for tumor-agnostic therapies rise, ROZLYTREK can potentially target a specialized yet valuable market segment. While competition from other TRK inhibitors ...
During a Case-Based Roundtable® event, Vamsidhar Velcheti, MD, discussed the TRIDENT-1 trial and practical considerations for ...
Sino Biopharm has a good financial position. As of December 2024, it has CNY 9.6 billion in cash on hand and CNY 9.6 billion in debt. Total debt outstanding is 14.7% of its total assets. Its capital ...
Fintel on MSN8d
UBS Upgrades Nuvalent (NUVL)Fintel reports that on March 14, 2025, UBS upgraded their outlook for Nuvalent (NasdaqGS:NUVL) from Neutral to Buy. Analyst ...
Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address ... a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback